UK's Cambridge Cognition posts 2025 revenue down 10%, misses estimates

Cambridge Cognition Holdings

19/01/2026 07:11

Overview

UK neuroscience tech firm's 2025 revenue fell 10%, missing analyst expectations

New sales orders in 2025 rose 73% to £12.8 mln

Order book at year-end increased 25% to £16.9 mln

Outlook

Company expects £8.5m to £9.0m revenue from order book in 2026

Cambridge Cognition sees growth in new sales orders in 2026

Company continues development in consumer health and wellness markets

Result Drivers

SALES ORDERS GROWTH - New sales orders increased by 73% to £12.8 mln due to strengthened commercial activities

ACADEMIC RESEARCH RECOVERY - Academic research segment returned to growth, contributing to sales order increase

CANTAB PATHWAY™ PILOT - Launched CANTAB Pathway™ in a pilot with a major European healthcare group

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
GBP 9.40 mln
GBP 9.51 mln (2 Analysts)
FY Order Backlog
GBP 16.90 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy."

Wall Street's median 12-month price target for Cambridge Cognition Holdings PLC is GBp53.00, about 89.3% above its January 16 closing price of GBp28.00

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 64 three months ago

Press Release: ID:nRSS3136Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)